Theravance Biopharma, Inc. - Multiplikator nilai perusahaan marang pendapatan TBPH

Theravance Biopharma (TBPH) EV/Sales dynamics demonstrate moderate pressure due to uncertainty surrounding ampreloxetine trials and reliance on legacy royalties, with the 5439.46 value capturing this metric. Management is focused on developing safe therapies for respiratory and gastrointestinal diseases. Simultaneously, the company is implementing ESG standards through inventory control and the minimization of chemical waste to improve healthcare accessibility.
Theravance Biopharma Inc - rincian analitis lan metrik utama (TBPH)

For Theravance Biopharma (TBPH), revenue-based valuation is critical due to its reliance on GSK royalties for Trelegy Ellipta. The company's EV/Sales multiple compares the total enterprise value, including debt minus cash, against annual turnover. This chart allows investors to filter out market noise and identify the actual overvaluation of the asset. An increase in this indicator reflects expectations for the R&D pipeline, while excessively high values signal a risk of capital correction.